Immatics N.V. (IMTX:NASDAQ) closed at $7.31 on October 23, 2026, down 3.05% on the day. The stock trades 41.1% below its 52-week high of $12.41 and 9.9% above its 52-week low of $6.65. Over the past year, it lost 28.2%. Immatics N.V. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, IMTX closed higher on 124 days (49%). Its best day was November 12, 2025 (+16.10%) and its worst was December 5, 2025 (-14.24%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 1 time.
Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
Find more stocks like IMTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.